Felbamate Shortage Update: What Patients Need to Know in 2026

If you rely on felbamate to manage treatment-resistant epilepsy, you may have heard the word "shortage" tossed around when you struggle to fill your prescription. Understanding exactly what is happening with felbamate availability—and what isn't—is essential to making informed decisions about your care in 2026.

Is There an Official Felbamate Shortage in 2026?

As of 2026, felbamate is not listed on the FDA's official Drug Shortages Database. The FDA defines a drug shortage as a situation in which the total supply of all clinically interchangeable versions of an FDA-regulated drug is inadequate to meet the current or projected demand at the patient level. By that standard, felbamate is not currently in shortage.

However, the absence of an official shortage doesn't mean the drug is easy to find. The FDA shortage label is a macro-level designation—it doesn't account for the fact that most retail pharmacies have chosen not to stock a medication at all due to low demand. That's the real challenge with felbamate in 2026.

A Brief History: Why Felbamate Had a Rocky Start

Felbamate was FDA-approved in 1993 with significant fanfare. It was the first new antiepileptic drug approved in more than a decade, and epilepsy specialists were hopeful about its effectiveness in refractory cases. At its peak in 1994, over 100,000 patients were taking it.

Then the adverse event reports began. Post-marketing surveillance identified rare but fatal cases of aplastic anemia—a life-threatening blood disorder—and acute liver failure in patients taking felbamate. A "Dear Doctor" letter was sent to hundreds of thousands of physicians recommending the drug only be continued in patients with severe epilepsy where the benefits clearly outweighed the risks. A black box warning was added to the prescribing information.

From a patient population of 100,000+ it fell to approximately 10,000–12,000 patients remaining on the drug by late 1994. Today, felbamate is prescribed to a very small, highly monitored group of patients for whom it provides seizure control no other drug has achieved. This dramatic reduction in use is the root cause of the availability challenges you face today.

What Actually Drives Felbamate Availability Problems in 2026

The current availability picture is shaped by several factors:

Limited retail stocking. Most chain pharmacies—including major retailers—don't keep felbamate on their shelves due to low turnover. The medication may be available through their distribution network but requires a special order.

Small number of active manufacturers. Generic felbamate has been available since 2011, made by companies including Alvogen, Taro, and Par Pharmaceutical. But because demand is low, only a limited number of manufacturers maintain active production, which can create localized supply gaps.

Distribution gaps in rural and underserved areas. Even where felbamate is available in the supply chain, it may not reach smaller or rural pharmacies. This geographic disparity is a real issue for patients outside major metropolitan areas.

Pharmacy closures. In the past two years, approximately 2,700 pharmacies have closed in the United States. For patients depending on specialty medications, each closure can mean losing one of the few local dispensing options.

What Should Patients Do Right Now?

If you're struggling to fill your felbamate prescription in 2026, take these steps:

Don't stop taking felbamate. Contact your neurologist before making any changes. Abruptly stopping can trigger dangerous rebound seizures.

Use medfinder to locate felbamate near you. medfinder contacts pharmacies in your area to check real-time stock and texts you the results.

Ask about a special order. Most pharmacies can order felbamate through their wholesaler within 24–72 hours. Plan your refills 10–14 days in advance.

Consider a mail-order specialty pharmacy. A 90-day supply from a specialty pharmacy reduces the frequency of access problems and may lower your out-of-pocket costs.

Talk to your neurologist about alternatives. If supply problems are chronic and causing dangerous supply gaps, your neurologist may want to revisit your treatment plan to determine whether another antiepileptic medication could provide adequate seizure control.

Looking Ahead: Will Felbamate Availability Improve?

There is ongoing research interest in felbamate derivatives and combination therapies that might preserve its anticonvulsant benefits while reducing the risk of aplastic anemia. A 2025 meta-analysis found that felbamate showed a 65% response rate and 17% seizure freedom rate in drug-resistant genetic generalized epilepsy, underscoring its value in specific patient populations. If safer formulations gain approval, demand—and therefore pharmacy stocking—could increase.

For now, the most important thing is proactive management. If you'd like to learn about alternatives in case your supply situation doesn't improve, see our article on alternatives to felbamate to prepare for a productive conversation with your neurologist.